Today, antagonists of C5 and C5a are approved by the FDA for the treatment of complement related disorders. C5a antagonists have a better safety profile than C5 because it does not inhibit membrane attack complex (MAC) formation and hence does not weaken the immune system's ability to kill ...
Nevertheless, in November 2011, the FDA announced that breast cancer indication for bevacizumab had been withdrawn, after concluding that the improvement in PFS observed in the AVADO and RIBBON 1 studies were not as consistent as the PFS improvement observed in the E2100 trial; furthermore, the ...
Ovarian cancer is one of the most fatal cancers in women worldwide. Cytoreductive surgery combined with platinum-based chemotherapy has been the current first-line treatment standard. Nevertheless, ovarian cancer appears to have a high recurrence rate an